---

Neuromuscular Blockade - Comprehensive Review

---

1. The Neuromuscular Junction (NMJ) - Physiological Basis

1. Action potential arrives at nerve terminal → voltage-gated Ca²⁺ channels open
2. Ca²⁺ influx triggers exocytosis of ACh vesicles (~200 quanta released per impulse; 10,000 molecules per quantum)
3. ACh diffuses across the synapse and binds both α subunits simultaneously
4. Conformational change opens the ion channel for ~1 ms (Na⁺ and Ca²⁺ in; K⁺ out)
5. End-plate potential (EPP) generated → propagates as action potential along T-tubule
6. Ca²⁺ release from sarcoplasmic reticulum → actin-myosin interaction → contraction
7. ACh rapidly hydrolyzed by acetylcholinesterase (AChE) in the synaptic cleft

---

2. Classification of Neuromuscular Blocking Drugs

• Morgan & Mikhail's Clinical Anesthesiology, 7e

---

3. Depolarizing Neuromuscular Blockade

Succinylcholine (Suxamethonium)

• Binds ACh receptors and generates an action potential (agonist) - this causes the initial fasciculations
• Unlike ACh, it is resistant to AChE - concentration in the cleft does not fall rapidly
• Prolonged depolarization → perijunctional Na⁺ channels inactivate and cannot reopen until the end plate repolarizes
• The end plate cannot repolarize as long as succinylcholine occupies the receptor → flaccid paralysis (Phase I block)

• Onset: 45-60 seconds (rapid - ideal for RSI)
• Duration: ~5-10 minutes (single bolus)
• Metabolism: Rapidly hydrolyzed by plasma butyrylcholinesterase (pseudocholinesterase) synthesized by the liver
• Standard intubating dose: 1-1.5 mg/kg IV; can also be given IM (4-5 mg/kg) for laryngospasm

• Heterozygous atypical gene (1:500): block prolonged to ~20-30 min
• Homozygous atypical (1:3000): block prolonged to 4-8 hours - requires mechanical ventilation until recovery
• The dibucaine number tests pseudocholinesterase quality:
  • Normal: dibucaine inhibits enzyme by 80% → dibucaine number 80
  • Homozygous atypical: inhibited by only 20% → dibucaine number 20
  • Measures function, not quantity of enzyme

• Sabiston Textbook of Surgery; Goldman-Cecil Medicine; Morgan & Mikhail's Clinical Anesthesiology

---

4. Nondepolarizing Neuromuscular Blockade

• Bind to one or both α subunits of the nicotinic ACh receptor without activating the ion channel
• Competitive antagonism - block is overcome by increasing ACh at the junction
• Also bind presynaptic α3β2 ACh receptors, reducing ACh release with subsequent nerve stimulation (causes fade on TOF)
• Neuromuscular blockade occurs even if only one α subunit is blocked

Classification by Duration and Chemical Class

1. Benzylisoquinolines - atracurium, cisatracurium, mivacurium (older: tubocurarine, doxacurium)
2. Aminosteroids - rocuronium, vecuronium, pancuronium (older: pipecuronium)
3. Asymmetric mixed-onium chlorofumarates - gantacurium (investigational)

---

Individual Drugs

Intermediate-Acting (20-50 minutes)

• ED₉₅: 0.3 mg/kg; intubating dose: 0.6 mg/kg (intermediate onset ~3 min) or 1.2 mg/kg for RSI (onset ~60 sec - equivalent to succinylcholine)
• Eliminated primarily via liver (biliary excretion) - prolonged in hepatic disease
• Vagolytic at high doses (mild tachycardia)
• Best reversed by sugammadex (can reverse even profound block in 3 min)
• Drug of choice for RSI when succinylcholine is contraindicated

• ED₉₅: 0.05 mg/kg; intubating dose: 0.1 mg/kg
• Eliminated by liver (50-60%) and kidney (40-50%) - use with caution in organ failure
• Minimal cardiovascular side effects - no histamine release, no vagolysis
• Metabolite (3-OH vecuronium) has ~50% activity - can accumulate with prolonged infusion in ICU

• Intubating dose: 0.5 mg/kg
• Unique: metabolized by Hofmann elimination (spontaneous chemical degradation at physiological pH and temperature) + plasma esterase hydrolysis - independent of hepatic and renal function
• Metabolite laudanosine can cause CNS excitation/seizures in high concentrations (theoretical concern in ICU)
• Releases histamine - can cause flushing, hypotension; administer slowly
• Preferred in severe renal/hepatic failure

• The 1R cis-1'R cis isomer of atracurium
• Same Hofmann elimination pathway - organ-independent metabolism
• 3-5x more potent than atracurium; much less histamine release than atracurium
• Preferred over atracurium in ICU settings (less laudanosine production per equivalent dose)
• Intubating dose: 0.15-0.2 mg/kg

• Shortest acting nondepolarizing agent (15-20 min); metabolized by pseudocholinesterase
• Prolonged in pseudocholinesterase deficiency (like succinylcholine)
• Releases histamine

Long-Acting (>60 minutes)

• Intubating dose: 0.1 mg/kg; duration 60-120 min
• Excreted mainly by kidney (60-80% unchanged) - prolonged in renal failure
• Has vagolytic and sympathomimetic effects → tachycardia and hypertension
• No histamine release
• Low cost; used less frequently now due to cardiovascular effects and long duration
• Goodman & Gilman's Pharmacological Basis of Therapeutics; Morgan & Mikhail's Clinical Anesthesiology; Sabiston Textbook of Surgery; Goldman-Cecil Medicine

---

5. Monitoring Neuromuscular Blockade

Stimulation Patterns

• 4 supramaximal stimuli at 2 Hz, every 10-15 seconds
• TOF ratio = T4/T1 amplitude
• Nondepolarizing block: progressive fade (T4 fades more than T1) due to presynaptic receptor blockade reducing ACh mobilization
• Depolarizing (Phase I) block: equal depression of all 4 twitches (no fade)
• TOF ratio <0.9 = residual paralysis (clinically relevant)
• TOF count of 0 = profound block; count 1-2 = deep block; count 3-4 = moderate block

• Used to assess profound block (TOF count = 0)
• 50 Hz tetanus for 5 sec, then single twitches at 1 Hz
• Used to predict time to spontaneous recovery or reversal with sugammadex

• Two short bursts of 50 Hz tetanus separated by 750 ms
• More sensitive than TOF for detecting residual block by tactile assessment

---

6. Reversal of Neuromuscular Blockade

A. Anticholinesterase Agents (Indirect - ACh buildup)

• Inhibits AChE → ACh accumulates → competitively displaces nondepolarizing NMBD from receptor
• Dose: 0.04-0.07 mg/kg (max ~5 mg)
• Must always be combined with an anticholinergic (glycopyrrolate 0.2 mg per 1 mg neostigmine, or atropine) to prevent muscarinic side effects (bradycardia, bronchospasm, increased secretions)
• Limitations:
  • Ineffective against deep/profound block (requires at least TOF count 2-3)
  • Ceiling effect - increasing dose does not provide more reversal once AChE is fully inhibited
  • Has an "appropriate" dose ceiling - paradoxically, too much neostigmine can cause weakness by causing persistent depolarization (neostigmine-induced weakness)
  • Takes 10-20 min for full effect

• Also an AChE inhibitor; faster onset (1-2 min) but shorter duration
• Dose: 0.5-1.0 mg/kg; combine with atropine (onset matched)
• Less reliable than neostigmine for dense blocks

B. Selective Relaxant Binding Agent: Sugammadex

• No anticholinergic needed (no muscarinic effects)
• Can reverse profound block - even immediately after RSI dose of rocuronium
• No ceiling effect
• Faster, more predictable reversal
• Preferred for patients with OSA (reduced postoperative pulmonary complications)

• Toremifene (antiestrogen) and fusidic acid can displace rocuronium from sugammadex complex - reduces efficacy
• Re-dosing of rocuronium after sugammadex: wait ≥24h for full dose; shorter-acting NMBDs (atracurium, cisatracurium) can be used immediately after sugammadex

---

7. Drug Interactions

• Patients on anticonvulsants require higher NMBDs doses but have accelerated recovery
• Magnesium (used in obstetrics for eclampsia) markedly potentiates nondepolarizing block - reduce doses by 25-50%
• Aminoglycosides cause neuromuscular blockade by reducing ACh release (presynaptic Ca²⁺ channel inhibition) - can be reversed by IV calcium
• Patients with myasthenia gravis are exquisitely sensitive to nondepolarizing NMBDs (10-fold); resistant to succinylcholine
• Morgan & Mikhail's Clinical Anesthesiology; Goldman-Cecil Medicine

---

8. Receptor Upregulation and Downregulation - Special States

---

9. Specific Clinical Applications

Rapid Sequence Intubation (RSI)

• Goal: secure airway quickly in patients at risk for pulmonary aspiration
• Classic: succinylcholine 1.5 mg/kg (onset 45-60 sec) - gold standard
• Alternative: rocuronium 1.2 mg/kg (onset ~60 sec) - preferred when succinylcholine is contraindicated; must have sugammadex 16 mg/kg immediately available as rescue
• Modified RSI with rocuronium + sugammadex is now widely practiced - Morgan & Mikhail's Clinical Anesthesiology

ICU Neuromuscular Blockade

• Used for: mechanical ventilation optimization, ARDS, status epilepticus refractory to sedation, tetanus, shivering during therapeutic hypothermia
• Cisatracurium is preferred in ICU (Hofmann elimination - no organ dependency; less laudanosine than atracurium)
• Risk: Critical illness myopathy/polyneuropathy - especially with concomitant corticosteroids (prolonged paralysis)
• Drug holiday ("train-of-four holiday") with daily monitoring recommended

Cardiac Surgery

• Nondepolarizing NMBDs preferred; pancuronium used historically (vagolysis offsets bradycardia from opioids/beta-blockers)
• Cisatracurium or vecuronium preferred when hemodynamic neutrality required

---

10. Residual Neuromuscular Blockade (RNMB)

• Defined as TOF ratio <0.9 at extubation
• Incidence: ~40% without proper reversal
• Risk factors: elderly, obese, obstructive sleep apnea, pulmonary disease, long-acting NMBDs, inadequate reversal
• Clinical consequences: upper airway obstruction, aspiration, hypoxia, reintubation, PONV
• Prevention: quantitative TOF monitoring (acceleromyography or electromyography), confirm TOF ratio ≥0.9 before extubation, prefer sugammadex over neostigmine for reversal
• Current recommendations strongly favor quantitative monitoring rather than clinical signs alone (head lift for 5 seconds, grip strength, tongue depressor test have poor sensitivity for detecting TOF ratios between 0.7-0.9)

---

11. Summary Table: Key NMBDs at a Glance

---

Key Takeaways

1. NMBDs do not cause unconsciousness or amnesia - awareness under anesthesia remains a risk
2. Succinylcholine is unmatched for speed of onset and ultra-short duration for RSI, but carries significant contraindications
3. Rocuronium at 1.2 mg/kg with sugammadex 16 mg/kg available provides a viable alternative to succinylcholine for RSI
4. Cisatracurium is the preferred NMBD in ICU/organ failure patients due to organ-independent Hofmann elimination
5. RNMB is common (~40%) and clinically dangerous - quantitative TOF monitoring and appropriate reversal (preferably sugammadex) are the standard of care
6. Sugammadex has replaced neostigmine as the preferred reversal agent for steroidal NMBDs in many centers - 2025 meta-analysis confirms superior outcomes

---

• Morgan & Mikhail's Clinical Anesthesiology, 7e
• Goodman & Gilman's Pharmacological Basis of Therapeutics
• Katzung's Basic and Clinical Pharmacology, 16th Edition
• Barash, Cullen & Stoelting's Clinical Anesthesia, 9e
• Sabiston Textbook of Surgery
• Goldman-Cecil Medicine, 2-Volume Set
• Recent meta-analyses: Sugammadex vs. neostigmine [PMID 40754949] and sugammadex coagulation effects [PMID 40269695]